BioLargo Strategic Partnership with Ikigai to Launch New Consumer Product
BioLargo, Inc. (OTCQB:BLGO) has received a 'go decision' from its partner Ikigai Holdings to expand television advertising for its new pet odor control product, 'POOPH'. The decision follows successful test marketing results, indicating strong potential for the product's commercial success. Ikigai CEO Jane Pak highlighted positive early feedback and plans for an extensive marketing campaign post-Christmas. BioLargo CEO Dennis P. Calvert mentioned the partnership could generate significant revenue, with Ikigai managing product rollout and distribution.
- Successful test marketing results for the 'POOPH' product.
- Ikigai's commitment to expanding marketing efforts indicates potential robust sales.
- BioLargo will earn royalties from the product sales, enhancing revenue stream.
- None.
Direct to Consumer Test Marketing is Successful
WESTMINSTER, CA / ACCESSWIRE / November 30, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it had received a "go decision" from its strategic partner, Ikigai Holdings, LLC, following positive results from the test-marketing phase of a new pet odor control product based on BioLargo's proprietary technology, branded "POOPH". The "go decision" indicates Ikigai's intent to expand television advertising with the goal to launch the product into big-box retailers, and formalizes their exclusive license to the product.
Ikigai Holdings, LLC is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products. Ikigai developed the "POOPH" brand, created television commercials and other advertising content, and then conducted a television direct-response test marketing campaign to assess the probability that the product would be a commercial success.
Jane Pak, Ikigai CEO, commented, "Early feedback from the test marketing of the POOPH product has been phenomenal. We have placed our initial purchase orders to support an expanded marketing campaign that will begin right after Christmas to gather additional data which will be instrumental in supporting accelerated consumer sales and establishing a strong transition from direct-to-consumer into retail. We are thrilled to see validation that POOPH can disrupt the highly established category of pet odor control products, and with these results, we are already thinking about more products based on BioLargo's technology."
BioLargo CEO Dennis P. Calvert commented, "Ikigai will purchase the POOPH products from us, and in addition, we receive a royalty on sales. They will finance and manage product roll-out, distribution, and marketing. We are excited about the potential for this partnership to create significant new revenue for both partners. The team at Ikigai is amazing!"
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.
View source version on accesswire.com:
https://www.accesswire.com/675172/BioLargo-Strategic-Partnership-with-Ikigai-to-Launch-New-Consumer-Product
FAQ
What is the news about BioLargo, Inc. and Ikigai Holdings?
What product is BioLargo launching with Ikigai Holdings?
What are the plans for the 'POOPH' product after the test marketing phase?
What revenue opportunities does BioLargo have with the 'POOPH' product?
